ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

化合物検索・調査依頼・データベース提供生理・薬理活性化合物/ポジコン

SR9011 (hydrochloride)

HY-16988A構造式

CAS No.
製品コード
HY-16988A
サプライヤー
Medchemexpress
純度
>98%
Target
Autophagy
参考納期(在庫有りの場合)
約5-10営業日

詳細情報

FormulaC23H32Cl2N4O3S
M.W.515.50
PathwayAutophagy
SolubilityDMSO: ? 32 mg/mL
備考SR9011 hydrochloride is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.
IC50 & Target: IC50: 790 nM (Rev-ErbBα), 560 nM (Rev-ErbBβ)[1]
In Vitro: SR9011 dose-dependently increases the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimeric Gal4 DNA Binding Domain (DBD) - REV-ERB ligand binding domain (LBD) α or β and a Gal4-responsive luciferase reporter (REV-ERBα IC50=790 nM, REV-ERBβ IC50=560 nM). SR9011 potently and efficaciously suppresses transcription in a cotransfection assay using full-length REV-ERBα along with a luciferase reporter driven by the Bmal1 promoter (SR9011 IC50=620 nM). SR9011 suppresses the expression ofBMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner[1] SR9011 suppresses proliferation of the breast cancer cell lines regardless of their ER or HER2 status. SR9011 appears to pause the cell cycle of the breast cancer cells prior to M phase. Cyclin A (CCNA2) is identified as a direct target gene of REV-ERB suggesting that suppression of expression of this cyclin by SR9011 may mediate the cell cycle arrest. Treatment with SR9011 results in an increase in cells in the G0/G1 phase and a decrease of cells in S and G2/M phase suggesting that activation of REV-ERB may be resulting in decreased transition from G1 to S phase and/or from S to G2/M phase[2].
In Vivo: SR9011 displays reasonable plasma exposure, thus, the expression of REV-ERB responsive genes is examined in the liver of mice treated with various doses of SR9011 for 6-days. The plasminogen activator inhibitor type 1 gene (Serpine1) is a REV-ERB target gene and displays dose-dependent suppression of expression in response to SR9011. The cholesterol 7α-hydroxylase (Cyp7a1) and sterol response element binding protein (Srepf1) genes have also been shown to be responsive to REV-ERB and are dose-dependently suppressed with increasing amounts of SR9011. After 12 days in D:D conditions mice are injected with a single dose of SR9011 or vehicle at CT6 (peak expression of Rev-erbα). Vehicle injection causes no disruption in circadian locomotor activity. However, administration of a single dose of SR9011 results in loss of locomotor activity during the subject dark phase. Normal activity returns the next circadian cycle, consistent with clearance of the drugs in less than 24h. The SR9011-dependent decrease in wheel running behavior in the mice under constant darkness conditions is dose-dependent and that the potency (ED50=56 mg/kg) is similar to the potency of SR9011-mediated suppression of a REV-ERB responsive gene, Srebf1 , in vivo (ED50=67mg/kg)[1].
URLhttp://https://www.medchemexpress.com/SR9011-hydrochloride.html

お問い合わせ(下記容量以外の容量をご希望される方は右側の容量記入欄に希望容量をご記入の上お問い合わせください。)

2mg : 24,400
お問い合わせ
5mg : 48,800
お問い合わせ
10mg : 85,400
お問い合わせ
お問い合わせ
  • 参考価格となりますので、実際の御見積金額と異なる場合がございます。予めご了承くださいますようお願い致します。
  • 輸入に関する法規制チェックは、御見積のご依頼を頂いた際に行います。
    (法規制によっては、稀に供給出来ない場合がございますので、あらかじめご了承ください。)
特許権侵害物質排除ポリシー
当社では、輸入取扱にかかる化学物質中に特許物質が含まれることにより特許権の侵害が生じないよう万全を期しておりますが、本製品一覧における全ての化学物質について特許登録の有無を調査することはきわめて困難であり、特許物質が含有されている場合があり得ます。
万一、当社製品一覧中に貴社の特許を侵害する物質が含有されていると判断される場合には、お手数ではございますが当社へご一報を頂けますと幸いです。直ちに該当品を本製品一覧から削除し、取扱いを停止する措置を執るものとします。